Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

- In lower risk myelodysplastic syndromes patients, longer-term treatment with luspatercept led to sustained increases in hemoglobin levels and transfusion independence -